Posts Tagged: Kaiser Family Foundation
A doctor and her patient have a consultation over medical care. (Photo: Andrei_R, via Shutterstock)
OPINION: As health care delivery evolves thanks to advances in data sharing and technology, it’s important that health systems harness the availability of these new tools to improve transparency, information dissemination and communications between doctor and patient, allowing them to better work together to make vital health decisions.
A pair of runners on a jaunt. (Photo: oneinchpunch, via Shutterstock)
OPINION: Between the COVID-19 pandemic and the upcoming election, people are tuning into the news to hear the latest numbers on both, yet when it comes to COVID-19, there is another set of numbers that Americans should be aware of—the toll the virus has taken on our physical and mental health.
People in support of the Affordable Care Act rally in Washington, D.C. (Photo: Rena Schild)
OPINION: Democrats and Republicans have found ways in the past to bridge the partisan divide on major health policy issues such as insurance for low-income children, the expansion of Medicare to include drugs, and changing the way Medicare pays for health care services that emphasize value. There’s no reason we can’t do the same to fix the Affordable Care Act, stabilize the marketplace and improve affordability and choice.
A physician prepares a syringe for use. (Photo: Shutterstock)
The results of a presidential election won by Republican Donald Trump has some in a panic. And with GOP majorities in both houses of Congress, Trump presumably can do just about anything. But California health advocates are not talking about abandoning the state’s healthcare system. They’re preparing for a fight.
A recent demonstration in support of curtailing drug prices. (Photo: California Nurses Association)
OPINION: The best argument for passing Proposition 61 to cut drug prices in California, may be SB 1010, a modest effort to require the drug manufacturers give more notice and some justification when jacking up prices. Though the bill would not have actually cut prices, it drew ferocious opposition from a who’s who list of major pharmaceutical firms. They won.